AcquisitionApr 29, 2026Pending
🇺🇸 United States
EBEmalex BiosciencesTPTeva Pharmaceuticals (Teva Pharmaceutical Industries Ltd.)
Healthcare › Pharmaceuticals
Equity value$700MEquity value
AnnouncedApr 29, 2026
ConsiderationCash
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentYes
Overview
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, agreed to acquire Emalex Biosciences, developer of ecopipam for pediatric Tourette syndrome, for $700 million in cash upfront plus up to $200 million in commercial milestones and royalties on net sales.
Deal rationale
The acquisition adds an NDA-ready, first-in-class neuroscience asset to Teva's innovative pipeline in support of its Pivot to Growth strategy.
AI-generated from the SEC filingPendingHealthcare › PharmaceuticalsUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | $700M | Headline figure |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Cash |
Advisors
Buy-side
EEvercore
Sell-side
CPCenterview PartnersPPHCP
Parties
Target
EBEmalex Biosciences
- Headquarters
- United States
- Ticker
- —
Acquirer
TPTeva Pharmaceuticals (Teva Pharmaceutical Industries Ltd.)
- Headquarters
- United States
- Ticker
- —
Seller
PBParagon Biosciences
- Headquarters
- —
- Ticker
- —